Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 11/2013

01.11.2013 | Original Article

Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression

verfasst von: Inbal Mishalian, Rachel Bayuh, Liran Levy, Lida Zolotarov, Janna Michaeli, Zvi Gregorio Fridlender

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

The role and characteristics of tumor-associated neutrophils (TAN) in cancer are poorly defined. We have recently shown that TAN can have anti-tumorigenic (N1) or pro-tumorigenic (N2) functions. An interesting unanswered question is how the phenotype of TAN is influenced by the ongoing evolvement of tumor microenvironment. We therefore studied the phenotype and effects of TAN at different time points during tumor progression. We used two models of murine tumor cancer cell lines—Lewis lung carcinoma (LLC) and AB12 (mesothelioma). Neutrophils were studied at early and late stages and compared to each other and to neutrophils from bone marrow/periphery of naïve mice. Although there was no difference in the number of neutrophils entering the tumor, we found that at early stages of tumor development, neutrophils were almost exclusively at the periphery of the tumor. Only at later stages, neutrophils were also found scattered among the tumor cells. We further found that TAN from early tumors are more cytotoxic toward tumor cells and produce higher levels of TNF-α, NO and H2O2. In established tumors, these functions are down-regulated and TAN acquire a more pro-tumorigenic phenotype. In line with this phenotype, only depletion of neutrophils at later stages of tumor development inhibited tumor growth, possibly due to their central location in the tumor. Our work adds another important layer to the understanding of neutrophils in cancer by further characterizing the changes in TAN during time. Additional research on the functional role of TAN and differences between subsets of TAN is currently underway.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Costello RT, Gastaut JA, Olive D (1999) Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz) 47(2):83–88 Costello RT, Gastaut JA, Olive D (1999) Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz) 47(2):83–88
4.
Zurück zum Zitat Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, Horng W, Fridlender G, Bayuh R, Worthen GS, Albelda SM (2012) Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE 7(2):e31524. doi:10.1371/journal.pone.0031524 PubMedCrossRef Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, Horng W, Fridlender G, Bayuh R, Worthen GS, Albelda SM (2012) Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE 7(2):e31524. doi:10.​1371/​journal.​pone.​0031524 PubMedCrossRef
6.
8.
Zurück zum Zitat Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116(8):2132–2141. doi:10.1172/JCI27648 PubMedCrossRef Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116(8):2132–2141. doi:10.​1172/​JCI27648 PubMedCrossRef
9.
Zurück zum Zitat Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180(4):2011–2017PubMed Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180(4):2011–2017PubMed
12.
Zurück zum Zitat Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555PubMedCrossRef Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555PubMedCrossRef
13.
Zurück zum Zitat Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A (2006) p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66(23):11432–11440. doi:10.1158/0008-5472.CAN-06-1867 PubMedCrossRef Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A, Sica A (2006) p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66(23):11432–11440. doi:10.​1158/​0008-5472.​CAN-06-1867 PubMedCrossRef
14.
16.
Zurück zum Zitat Pekarek LA, Starr BA, Toledano AY, Schreiber H (1995) Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181(1):435–440PubMedCrossRef Pekarek LA, Starr BA, Toledano AY, Schreiber H (1995) Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181(1):435–440PubMedCrossRef
17.
18.
Zurück zum Zitat Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, Sendo F, Kobayashi M, Hosokawa M (2003) Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol 163(6):2221–2232. doi:10.1016/S0002-9440(10)63580-8 PubMedCrossRef Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, Sendo F, Kobayashi M, Hosokawa M (2003) Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol 163(6):2221–2232. doi:10.​1016/​S0002-9440(10)63580-8 PubMedCrossRef
19.
Zurück zum Zitat Colombo MP, Lombardi L, Stoppacciaro A, Melani C, Parenza M, Bottazzi B, Parmiani G (1992) Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. J Immunol 149(1):113–119PubMed Colombo MP, Lombardi L, Stoppacciaro A, Melani C, Parenza M, Bottazzi B, Parmiani G (1992) Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells. J Immunol 149(1):113–119PubMed
20.
Zurück zum Zitat Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, Simpson AJ, Old LJ, Cui Z (2006) Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA 103(20):7753–7758. doi:10.1073/pnas.0602382103 PubMedCrossRef Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, Simpson AJ, Old LJ, Cui Z (2006) Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA 103(20):7753–7758. doi:10.​1073/​pnas.​0602382103 PubMedCrossRef
21.
Zurück zum Zitat Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97(2):339–345PubMedCrossRef Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97(2):339–345PubMedCrossRef
22.
23.
Zurück zum Zitat Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S (2010) Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 120(4):1151–1164. doi:10.1172/JCI37223 PubMedCrossRef Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S (2010) Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 120(4):1151–1164. doi:10.​1172/​JCI37223 PubMedCrossRef
26.
Zurück zum Zitat Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, Kaiser LR, Ling L, Albelda SM (2008) Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 68(24):10247–10256. doi:10.1158/0008-5472.CAN-08-1494 PubMedCrossRef Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, Kaiser LR, Ling L, Albelda SM (2008) Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 68(24):10247–10256. doi:10.​1158/​0008-5472.​CAN-08-1494 PubMedCrossRef
27.
29.
Zurück zum Zitat Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA (2000) The neutrophil as a cellular source of chemokines. Immunol Rev 177:195–203PubMedCrossRef Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA (2000) The neutrophil as a cellular source of chemokines. Immunol Rev 177:195–203PubMedCrossRef
30.
Zurück zum Zitat Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107(5):2112–2122. doi:10.1182/blood-2005-01-0428 PubMedCrossRef Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107(5):2112–2122. doi:10.​1182/​blood-2005-01-0428 PubMedCrossRef
31.
Zurück zum Zitat Sugai H, Kono K, Takahashi A, Ichihara F, Kawaida H, Fujii H, Matsumoto Y (2004) Characteristic alteration of monocytes with increased intracellular IL-10 and IL-12 in patients with advanced-stage gastric cancer. J Surg Res 116(2):277–287. doi:10.1016/j.jss.2003.10.008 PubMedCrossRef Sugai H, Kono K, Takahashi A, Ichihara F, Kawaida H, Fujii H, Matsumoto Y (2004) Characteristic alteration of monocytes with increased intracellular IL-10 and IL-12 in patients with advanced-stage gastric cancer. J Surg Res 116(2):277–287. doi:10.​1016/​j.​jss.​2003.​10.​008 PubMedCrossRef
32.
Zurück zum Zitat Tsai CS, Chen FH, Wang CC, Huang HL, Jung SM, Wu CJ, Lee CC, McBride WH, Chiang CS, Hong JH (2007) Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys 68(2):499–507. doi:10.1016/j.ijrobp.2007.01.041 PubMedCrossRef Tsai CS, Chen FH, Wang CC, Huang HL, Jung SM, Wu CJ, Lee CC, McBride WH, Chiang CS, Hong JH (2007) Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys 68(2):499–507. doi:10.​1016/​j.​ijrobp.​2007.​01.​041 PubMedCrossRef
33.
Zurück zum Zitat Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11(8):519–531. doi:10.1038/nri3024 PubMedCrossRef Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11(8):519–531. doi:10.​1038/​nri3024 PubMedCrossRef
35.
Zurück zum Zitat Beutler BA (1999) The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 57:16–21PubMed Beutler BA (1999) The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 57:16–21PubMed
36.
Zurück zum Zitat Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2):135–141PubMedCrossRef Balkwill F (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2):135–141PubMedCrossRef
40.
Zurück zum Zitat Dallegri F, Patrone F, Frumento G, Sacchetti C (1984) Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst 73(2):331–339PubMed Dallegri F, Patrone F, Frumento G, Sacchetti C (1984) Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. J Natl Cancer Inst 73(2):331–339PubMed
41.
Zurück zum Zitat Gerrard TL, Cohen DJ, Kaplan AM (1981) Human neutrophil-mediated cytotoxicity to tumor cells. J Natl Cancer Inst 66(3):483–488PubMed Gerrard TL, Cohen DJ, Kaplan AM (1981) Human neutrophil-mediated cytotoxicity to tumor cells. J Natl Cancer Inst 66(3):483–488PubMed
42.
Zurück zum Zitat Katano M, Torisu M (1982) Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50(1):62–68PubMedCrossRef Katano M, Torisu M (1982) Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50(1):62–68PubMedCrossRef
43.
Zurück zum Zitat Dallegri F, Ottonello L, Ballestrero A, Dapino P, Ferrando F, Patrone F, Sacchetti C (1991) Tumor cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. Inflammation 15(1):15–30PubMedCrossRef Dallegri F, Ottonello L, Ballestrero A, Dapino P, Ferrando F, Patrone F, Sacchetti C (1991) Tumor cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. Inflammation 15(1):15–30PubMedCrossRef
44.
Zurück zum Zitat Lichtenstein A, Seelig M, Berek J, Zighelboim J (1989) Human neutrophil-mediated lysis of ovarian cancer cells. Blood 74(2):805–809PubMed Lichtenstein A, Seelig M, Berek J, Zighelboim J (1989) Human neutrophil-mediated lysis of ovarian cancer cells. Blood 74(2):805–809PubMed
45.
Zurück zum Zitat Zivkovic M, Poljak-Blazi M, Egger G, Sunjic SB, Schaur RJ, Zarkovic N (2005) Oxidative burst and anticancer activities of rat neutrophils. BioFactors 24(1–4):305–312PubMedCrossRef Zivkovic M, Poljak-Blazi M, Egger G, Sunjic SB, Schaur RJ, Zarkovic N (2005) Oxidative burst and anticancer activities of rat neutrophils. BioFactors 24(1–4):305–312PubMedCrossRef
46.
Zurück zum Zitat Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, Overall CM, Shapiro SD, Lopez-Otin C (2003) Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35(3):252–257. doi:10.1038/ng1249 PubMedCrossRef Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, Overall CM, Shapiro SD, Lopez-Otin C (2003) Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 35(3):252–257. doi:10.​1038/​ng1249 PubMedCrossRef
48.
Zurück zum Zitat Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, Parmiani G, Colombo MP (1993) Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 178(1):151–161PubMedCrossRef Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, Parmiani G, Colombo MP (1993) Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 178(1):151–161PubMedCrossRef
49.
Metadaten
Titel
Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression
verfasst von
Inbal Mishalian
Rachel Bayuh
Liran Levy
Lida Zolotarov
Janna Michaeli
Zvi Gregorio Fridlender
Publikationsdatum
01.11.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 11/2013
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-013-1476-9

Weitere Artikel der Ausgabe 11/2013

Cancer Immunology, Immunotherapy 11/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.